Factors Affecting Disease Recurrence and the Role of Secondary Therapies in the Management for Patients with Recurrent Ovarian Carcinoma

Rongyu Zang,Zhiyi Zhang,Shumo Cai
DOI: https://doi.org/10.3760/j.issn:0529-567x.2002.09.011
2002-01-01
Abstract:OBJECTIVE:To identify variants affecting disease recurrence and clarify the role of re-debulking surgery and second-line chemotherapy in the management of recurrent advanced epithelial ovarian cancer (AEOC). METHODS:One hundred and sixty-seven patients with recurrent AEOC treated in our hospital between Jan. 1986 and Dec. 1997 were retrospectively reviewed. Survival was calculated by Kaplan-Meier method with difference in survival estimated by Log-rank test. Independent prognostic factors were identified by the COX stepwise regression model, and variants associated with disease recurrence were found by logistic stepwise regression methods. RESULTS:The median age was 51 (range 26-71) years. Sixty patients underwent re-debulking surgery, 23 of them with residual disease = 1 cm. There was a significant difference in survival between optimal and sub-optimal groups, with an estimated median survival of 20 and 10 months, respectively (chi(2) = 9.42, P = 0.021). When patients with sub-optimal surgical results were compared with those who had chemotherapy alone, there was a significant difference in median survival, 10 vs. 13 months (chi(2) = 4.38, P = 0.036 4). Age of the patients, refractory ascites, second-line chemotherapy, and residual disease after primary surgery were independent prognostic factors of survival identified by COX regression analysis. Logistic stepwise regression analysis revealed that age, platinum-based chemotherapy, neoadjuvant chemotherapy, and the size of residual disease after primary surgical cytoreduction were factors affecting progression-free interval. CONCLUSIONS:The age at diagnosis, residual disease, first-line chemotherapy, and neoadjuvant chemotherapy are factors affecting disease recurrence. Patients received second-line chemotherapy and with residual disease = 1 cm after secondary surgery experience a better prognosis than those without receiving second-line chemotherapy or with residual disease > 1 cm after secondary cytoreduction.
What problem does this paper attempt to address?